Royalty Pharma (NASDAQ:RPRX) Downgraded by StockNews.com to Hold

StockNews.com lowered shares of Royalty Pharma (NASDAQ:RPRX) from a buy rating to a hold rating in a research report sent to investors on Monday.

Several other analysts have also commented on RPRX. Morgan Stanley increased their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Citigroup reduced their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, The Goldman Sachs Group boosted their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Stock Down 0.7 %

Shares of RPRX stock opened at $27.00 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The stock has a market cap of $16.13 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 3.97 and a beta of 0.46. The business’s fifty day moving average is $27.99 and its 200-day moving average is $27.57. Royalty Pharma has a 1 year low of $25.20 and a 1 year high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. During the same period in the previous year, the company earned $0.85 earnings per share. Equities analysts expect that Royalty Pharma will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.21 per share. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.11%. Royalty Pharma’s dividend payout ratio is 62.69%.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc increased its holdings in shares of Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,043 shares during the period. Gladius Capital Management LP acquired a new position in Royalty Pharma in the 2nd quarter valued at approximately $32,000. Blue Trust Inc. lifted its position in Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 943 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Royalty Pharma during the 1st quarter valued at $46,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 655 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.